138 related articles for article (PubMed ID: 35100683)
1. Primer on Hereditary Cancer Predisposition Genes Included Within Somatic Next-Generation Sequencing Panels.
Akras Z; Bungo B; Leach BH; Marquard J; Ahluwalia M; Carraway H; Grivas P; Sohal DPS; Funchain P
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100683
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
3. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
4. What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?
Leite ACR; Suzuki DA; Pereira AAL; Machado NP; Barroso-Sousa R; Correa TS; Moura FC; Morbeck IAP; Gumz BP; Faria LDBB; Fernandes GDS; Sandoval RL
Front Oncol; 2022; 12():963910. PubMed ID: 36132150
[TBL] [Abstract][Full Text] [Related]
5. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel.
Coffee B; Cox HC; Kidd J; Sizemore S; Brown K; Manley S; Mancini-DiNardo D
Cancer Genet; 2017 Feb; 211():5-8. PubMed ID: 28279308
[TBL] [Abstract][Full Text] [Related]
6. The impact of hereditary cancer gene panels on clinical care and lessons learned.
Okur V; Chung WK
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162654
[TBL] [Abstract][Full Text] [Related]
7. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
[TBL] [Abstract][Full Text] [Related]
8. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond
Barbosa A; Pinto P; Peixoto A; Guerra J; Pinto C; Santos C; Pinheiro M; Escudeiro C; Bartosch C; Silva J; Teixeira MR
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008098
[TBL] [Abstract][Full Text] [Related]
9. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Piccinin C; Panchal S; Watkins N; Kim RH
Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
[No Abstract] [Full Text] [Related]
10. Discrepancies between tumor genomic profiling and germline genetic testing.
Pauley K; Koptiuch C; Greenberg S; Kohlmann W; Jeter J; Colonna S; Werner T; Kinsey C; Gilcrease G; Weis J; Whisenant J; Florou V; Garrido-Laguna I
ESMO Open; 2022 Aug; 7(4):100526. PubMed ID: 35780590
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
12. A Case of Isolated Myeloid Sarcoma Associated With Germline
Walker M; Folstad M; Smith-Simmer K; Reinig E; Nadiminti K; Lovrien L; Churpek JE; Banaszak LG
J Hematol; 2022 Apr; 11(2):71-76. PubMed ID: 35573754
[TBL] [Abstract][Full Text] [Related]
13. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
[TBL] [Abstract][Full Text] [Related]
14. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
15. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
[TBL] [Abstract][Full Text] [Related]
16. Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition.
Martin-Morales L; Rofes P; Diaz-Rubio E; Llovet P; Lorca V; Bando I; Perez-Segura P; de la Hoya M; Garre P; Garcia-Barberan V; Caldes T
PLoS One; 2018; 13(9):e0203885. PubMed ID: 30256826
[TBL] [Abstract][Full Text] [Related]
17. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
18. Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing.
Stanislaw C; Xue Y; Wilcox WR
Cancer Biol Med; 2016 Mar; 13(1):55-67. PubMed ID: 27144062
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.
Spurdle AB; Bowman MA; Shamsani J; Kirk J
Mod Pathol; 2017 Aug; 30(8):1048-1068. PubMed ID: 28452373
[TBL] [Abstract][Full Text] [Related]
20. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
